Valuation: Avicanna Inc.

Market Cap 1.45Cr 1.01Cr 90.13L 84.29L 76.81L 98Cr 1.47Cr 10Cr 3.95Cr 50Cr 3.81Cr 3.73Cr 159.82Cr P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 1.42Cr 99.51L 88.38L 82.65L 75.32L 96Cr 1.44Cr 10Cr 3.87Cr 49Cr 3.74Cr 3.65Cr 156.72Cr EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
78.71%
Yield 2024 *
-
Yield 2025 -
1 day-9.95%
1 week-5.78%
Current month-9.95%
1 month-22.81%
3 months-32.00%
6 months-31.60%
Current year-57.00%
1 week 0.07
Extreme 0.0697
0.08
1 month 0.07
Extreme 0.0697
0.09
Current year 0.07
Extreme 0.06842
0.18
1 year 0.07
Extreme 0.06842
0.22
3 years 0.07
Extreme 0.06842
0.53
5 years 0.07
Extreme 0.06842
0.76
10 years 0
Extreme 0
3.53
Manager TitleAgeSince
Sales & Marketing - 01/05/2015
Chief Executive Officer 39 26/11/2016
Director of Finance/CFO - 15/09/2025
Director TitleAgeSince
Chairman 39 26/11/2016
Director/Board Member - 22/10/2018
Director/Board Member - 01/01/2026
Change 5-day change 1-year change 3-year change Capi.($)
-9.95%-5.78% - - 1.02Cr
+4.16%-0.36%+49.37%+94.17% 7.45TCr
-0.61%+0.81%+27.25%+80.21% 6.01TCr
-2.54%-1.65%+4.86%+33.32% 4.82TCr
-2.39%-4.86%+28.40%+34.96% 4.43TCr
+1.12%+4.04%+353.39%+694.52% 4.4TCr
-1.36%+0.03%+7.43%+101.72% 4.16TCr
+3.32%+3.49%+11.18%+51.23% 3TCr
+4.77%+6.16%+36.77%+22.78% 2.93TCr
-3.19%-9.37%-25.20%+334.21% 2.49TCr
Average -0.65%+1.97%+54.83%+160.79% 4.41TCr
Weighted average by Cap. +0.52%+1.83%+59.09%+151.98%

Financials

2024 2025
Net sales 2.55Cr 1.79Cr 1.59Cr 1.48Cr 1.35Cr 172.01Cr 2.58Cr 18Cr 6.95Cr 88Cr 6.71Cr 6.56Cr 281.38Cr 2.55Cr 1.79Cr 1.59Cr 1.49Cr 1.35Cr 172.15Cr 2.58Cr 18Cr 6.96Cr 88Cr 6.71Cr 6.57Cr 281.59Cr
Net income -36.18L -25.39L -22.55L -21.09L -19.22L -24Cr -36.67L -2.55Cr -98.75L -12Cr -95.32L -93.25L -40Cr -27.59L -19.36L -17.2L -16.08L -14.66L -19Cr -27.97L -1.95Cr -75.32L -9.49Cr -72.7L -71.12L -30Cr
Net Debt -3L -2L -2L -2L -2L -2.29Cr -3L -23.89L -9L -1.17Cr -9L -9L -3.74Cr -3L -2L -2L -2L -1L -1.9Cr -3L -19.79L -8L -96.56L -7L -7L -3.1Cr
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
01/26/01 $0.0697 -9.95% 5,20,200
30/26/30 $0.0774 +1.84% 300
29/26/29 $0.0760 -2.69% 31,350
28/26/28 $0.0781 +5.11% 700
25/26/25 $0.0743 +0.44% 800